Krystal Biotech

Update in progress

KRYS (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Krystal Biotech, Inc. is a commercial-stage biotechnology company that discovers, develops, manufactures, and markets genetic medicines to treat high-need diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, B-VEC) for dystrophic epidermolysis bullosa (DEB) and is advancing multiple candidates, including KB803 (ocular DEB), KB801 (neurotrophic keratitis), KB407 (cystic fibrosis), KB111 (Hailey-Hailey), KB301 (aesthetic skin conditions), and others in clinical trials. Founded in 2016 and based in Pittsburgh, PA.

Company score

Sentiment: 0.40; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.11; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.42; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.19; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.29; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive